Skip to main content

Venn Life CEO Richardson comments on Kinesis deal

Venn Life CEO Richardson comments on Kinesis deal

Tony Richardson, chief executive Venn Life Sciences (LON:VENN), says the company’s acquisition of Dutch drug consultancy Kinesis allows it to pair early and late-stage drug development together.

Source: ProactiveInvestors.co.uk